ArticleInternational journal of clinical and experimental pathology2015
Expression of alpha B crystallin and BCL2 in patients with infiltrating ductal carcinoma.
Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 10 citations in OpenAlex.
- The multifaceted nature of αB-crystallin.Cell stress & chaperones · 2020Review
- Therapeutic Effect of Mongolian Medicine RuXian-I on Hyperplasia of Mammary Gland Induced by Estrogen/Progesterone through CRYAB-Promoted Apoptosis.Evidence-based complementary and alternative medicine : eCAM · 2020Article
- Progression of the role of CRYAB in signaling pathways and cancers.OncoTargets and therapy · 2019Review
- Alpha B-crystallin C-802G polymorphism and colorectal cancer susceptibility and clinical outcome in Chinese population.Scientific reports · 2018Article
- BI-RADS 3-5 microcalcifications can preoperatively predict breast cancer HER2 and Luminal a molecular subtype.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alpha B crystallin was characterized as a negative prognostic factor in breast cancer. BCL2 has an antiapoptotic role and sustains cell survival in vitro, ironically BCL2 expression has been associated with a good prognosis of breast cancer patients. To investigate the significance of alpha B crystallin and BCL2 expression in breast cancer and the relationship between these proteins, we performed immunohistochemical staining for both proteins in human breast cancer tissues. In the present study, overexpression of alpha B crystallin was observed more frequently in triple negative cancer (9/20, 45%) than in luminal type cancer (8/53, 15.1%, P=0.02161). BCL2 tended to be more highly expressed in luminal type cancer than in HER2 and triple negative cancer types (luminal: 36/53, 68%, HER2: 2/9, 22%, triple negative: 7/20 35%, P=0.008652). In multivariate analysis using ANCOVA, alpha B crystallin was related to short overall survival (P=0.017173). These findings suggest that alpha B crystallin is an independent prognostic factor of infiltrating ductal carcinoma. BCL2 was not associated with survival in multivariate analysis using ANCOVA. Thus, in our study BCL2 was not an independent prognostic indicator.
Indexed as
Identifiers
26464626PMC4583858W2179352125What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.